Literature DB >> 15186601

Intraobserver, interobserver, and day-to-day reproducibility of quantitative 99mTc-HYNIC annexin-V imaging in head and neck carcinoma.

Hubert Vermeersch1, Hamphrey Ham, Sylvie Rottey, Christophe Lahorte, Federica Corsetti, Rudi Dierckx, Neil Steinmetz, Christophe Van de Wiele.   

Abstract

RATIONALE: For clinical application, a sufficient reproducibility of 99mTc-HYNIC annexin-V quantitative uptake measurements must be demonstrated to allow a study of cell-death changes induced by chemotherapy over time and intersubject. Thus, the aim of this study was to estimate the intra-, inter-, and day-to-day reproducibility of quantitative 99mTc-HYNIC annexin-V tumor uptake values in patients suffering from head and neck carcinomas.
METHODS: Thirteen (13) patients suffering from clinically suspected, histologically confirmed squamous head and neck carcinomas were prospectively included in the study. All patients were scheduled to undergo a spiral computed tomography scan and two 99mTc-HYNIC annexin-V scintigraphies within 3-5 days from each other, referred to as day 1 and day 2 of scintigraphy. The percentage of uptake of the injected dose of 99mTc-HYNIC annexin-V in tumor lesions on scintigrams divided by the tumor volume, as derived from CT, was determined twice within an interval of 2 weeks by observer 1 and once by observer 2 on day 1 of scintigraphy and once on day 2 of scintigraphy by observer 1.
RESULTS: The mean of the difference for the intra-, inter-, and day-to-day measurements were -3.4%, 2.4%, and -6%, respectively. No systematic bias was observed for the mean of the differences for the intra-, inter-, and day-to-day measurements. The respective confidence intervals for the mean of the differences of intra-, inter-, and day-to-day variability were -8.2%-1.4%, -2.9%-7.8%, and -14.7%-2.7%.
CONCLUSION: The reproducibility of quantitative 99mTc-HYNIC annexin-V tumor uptake measurements using a manual method appears to be acceptable for clinical use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15186601     DOI: 10.1089/108497804323071986

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  13 in total

Review 1.  (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.

Authors:  Tarik Z Belhocine; Francis G Blankenberg; Marina S Kartachova; Larry W Stitt; Jean-Luc Vanderheyden; Frank J P Hoebers; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-08-16       Impact factor: 9.236

2.  Imaging apoptosis in the eye.

Authors:  M F Cordeiro; C Migdal; P Bloom; F W Fitzke; S E Moss
Journal:  Eye (Lond)       Date:  2011-03-25       Impact factor: 3.775

Review 3.  Molecular imaging: 18F-FDG PET and a whole lot more.

Authors:  Todd E Peterson; H Charles Manning
Journal:  J Nucl Med Technol       Date:  2009-08-19

4.  Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V.

Authors:  Francis G Blankenberg
Journal:  Proc Am Thorac Soc       Date:  2009-08-15

5.  Prognostic value of 99mTc-HYNIC annexin-V imaging in squamous cell carcinoma of the head and neck.

Authors:  David Loose; Hubert Vermeersch; Filip De Vos; Philippe Deron; Guido Slegers; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-29       Impact factor: 9.236

Review 6.  Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.

Authors:  R Adam Smith; Saffet Guleryuz; H Charles Manning
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01

7.  Transbilayer phospholipids molecular imaging.

Authors:  Tarik Z Belhocine; Frank S Prato
Journal:  EJNMMI Res       Date:  2011-08-22       Impact factor: 3.138

Review 8.  SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic.

Authors:  Xiaobo Wang; Han Feng; Shichao Zhao; Junling Xu; Xinyu Wu; Jing Cui; Ying Zhang; Yuhua Qin; Zhiguo Liu; Tang Gao; Yongju Gao; Wenbin Zeng
Journal:  Oncotarget       Date:  2017-03-21

9.  99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.

Authors:  Frédéric L W V J Schaper; Chris P Reutelingsperger
Journal:  Cancers (Basel)       Date:  2013-05-15       Impact factor: 6.639

10.  99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy.

Authors:  Frank J P Hoebers; Marina Kartachova; Josien de Bois; Michiel W M van den Brekel; Harm van Tinteren; Marcel van Herk; Coen R N Rasch; Renato A Valdés Olmos; Marcel Verheij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.